Eli Lilly Weight Loss Drugs Boom: Can Foundayo Defend Margins?
Can Eli Lilly’s new Foundayo pill and GLP‑1 pipeline keep its obesity lead as a brutal price war erupts? Maik Kemper Editor in Chief Conclusion…
Eli Lilly Retatrutide Boom: Triple-Agonist Trial Shock
Can Eli Lilly Retatrutide’s powerful Phase 3 diabetes data reignite confidence in the GLP-1 boom despite rising competitive and pricing fears? Maik Kemper Editor in…